News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
74,115 Results
Type
Article (6963)
Company Profile (15)
Press Release (67133)
Multimedia
Podcasts (14)
Webinars (1)
Section
Business (14501)
Career Advice (1119)
Deals (2623)
Drug Delivery (23)
Drug Development (16143)
Employer Resources (37)
FDA (2005)
Job Trends (2184)
News (33840)
Policy (3151)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Standard (2)
Academia (505)
Accelerated approval (13)
Adcomms (8)
Allergies (30)
Alliances (3519)
ALS (55)
Alzheimer's disease (330)
Antibody-drug conjugate (ADC) (116)
Approvals (2161)
Artificial intelligence (129)
Autoimmune disease (78)
Automation (10)
Bankruptcy (26)
Best Places to Work (1945)
Biosimilars (48)
Biotechnology (5)
Bladder cancer (101)
Brain cancer (25)
Breast cancer (261)
Cancer (2205)
Cardiovascular disease (138)
Career advice (871)
Career pathing (17)
CAR-T (185)
CDC (4)
Cell therapy (381)
Cervical cancer (13)
Clinical research (14692)
Collaboration (427)
Company closure (1)
Compensation (189)
Complete response letters (4)
COVID-19 (1025)
CRISPR (32)
C-suite (125)
Cystic fibrosis (37)
Data (2561)
Depression (30)
Diabetes (218)
Diagnostics (751)
Digital health (4)
Diversity (1)
Diversity, equity & inclusion (6)
Drug discovery (54)
Drug pricing (34)
Drug shortages (3)
Duchenne muscular dystrophy (50)
Earnings (8723)
Editorial (17)
Employer branding (7)
Employer resources (35)
Events (13078)
Executive appointments (134)
FDA (3054)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (6)
Funding (408)
Gene editing (65)
Generative AI (8)
Gene therapy (182)
GLP-1 (296)
Government (753)
Grass and pollen (4)
Guidances (115)
Healthcare (2491)
HIV (34)
Huntington's disease (14)
IgA nephropathy (18)
Immunology and inflammation (82)
Immuno-oncology (26)
Indications (41)
Infectious disease (1099)
Inflammatory bowel disease (48)
Inflation Reduction Act (1)
Influenza (26)
Intellectual property (41)
Interviews (220)
IPO (1481)
IRA (5)
Job creations (407)
Job search strategy (737)
JPM (29)
Kidney cancer (8)
Labor market (40)
Layoffs (122)
Leadership (19)
Legal (451)
Liver cancer (30)
Longevity (4)
Lung cancer (305)
Lymphoma (285)
Machine learning (10)
Management (10)
Manufacturing (137)
MASH (38)
Medical device (1149)
Medtech (1156)
Mergers & acquisitions (1367)
Metabolic disorders (414)
Multiple sclerosis (91)
NASH (4)
Neurodegenerative disease (108)
Neuropsychiatric disorders (20)
Neuroscience (711)
Neurotech (1)
NextGen: Class of 2026 (721)
Non-profit (514)
Now hiring (6)
Obesity (161)
Opinion (84)
Ovarian cancer (86)
Pain (31)
Pancreatic cancer (68)
Parkinson's disease (80)
Partnered (9)
Patents (83)
Patient recruitment (148)
Peanut (11)
People (3325)
Pharmaceutical (8)
Pharmacy benefit managers (4)
Phase 1 (5244)
Phase 2 (6823)
Phase 3 (4798)
Pipeline (1774)
Policy (47)
Postmarket research (359)
Preclinical (1752)
Press Release (8)
Prostate cancer (94)
Psychedelics (15)
Radiopharmaceuticals (30)
Rare diseases (228)
Real estate (298)
Recruiting (20)
Regulatory (3258)
Reports (14)
Research institute (470)
Resumes & cover letters (231)
Rett syndrome (16)
RNA editing (2)
RSV (24)
Schizophrenia (42)
Series A (58)
Series B (52)
Sickle cell disease (41)
Special edition (11)
Spinal muscular atrophy (31)
Sponsored (15)
Startups (304)
Stomach cancer (6)
Supply chain (20)
Tariffs (21)
The Weekly (14)
Vaccines (313)
Venture capital (21)
Weight loss (109)
Women's health (15)
Worklife (12)
Date
Last 7 days (155)
Last 30 days (576)
Last 365 days (8870)
2026 (761)
2025 (8988)
2024 (6851)
2023 (5920)
2022 (6986)
2021 (7466)
2020 (6690)
2019 (4927)
2018 (3670)
2017 (3583)
2016 (2930)
2015 (3515)
2014 (2097)
2013 (1402)
2012 (1462)
2011 (1433)
2010 (1045)
Location
Africa (210)
Alabama (15)
Arizona (19)
Arkansas (2)
Asia (5242)
Australia (1077)
California (3159)
Canada (676)
China (387)
Colorado (84)
Connecticut (133)
Delaware (155)
Europe (12690)
Florida (252)
Georgia (67)
Hawaii (2)
Idaho (10)
Illinois (262)
India (10)
Indiana (93)
Iowa (14)
Japan (179)
Kansas (7)
Kentucky (7)
Louisiana (4)
Maine (7)
Maryland (358)
Massachusetts (2334)
Michigan (52)
Minnesota (98)
Mississippi (2)
Missouri (44)
Nebraska (1)
Nevada (37)
New Hampshire (14)
New Jersey (1023)
New Mexico (2)
New York (853)
North Carolina (227)
North Dakota (3)
Northern California (1517)
Ohio (68)
Oregon (10)
Pennsylvania (466)
Puerto Rico (3)
Rhode Island (10)
South America (204)
South Carolina (13)
Southern California (1208)
Tennessee (33)
Texas (547)
United States (10528)
Utah (33)
Virginia (62)
Washington D.C. (13)
Washington State (280)
West Virginia (1)
Wisconsin (40)
74,115 Results for "t2 biosystems.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
CAR-T
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move
The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 million upfront in January 2024.
October 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases
January 8, 2026
·
3 min read
Press Releases
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
December 22, 2025
·
6 min read
Press Releases
Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
December 23, 2025
·
4 min read
Press Releases
A2 Biotherapeutics Presents Initial Safety and Efficacy Data from Ongoing Phase 1/2 EVEREST-2 Study, Including First Report of a Complete Response to CAR T-Cell Therapy in a Patient with NSCLC
November 10, 2025
·
8 min read
Press Releases
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
November 4, 2025
·
4 min read
Mergers & acquisitions
The Top Big Pharmas Have $1.2T in Stretch M&A Firepower Available
The two most historically deal-conservative Big Pharmas have the most money to play with for a major M&A transaction, according to a recent Stifel analysis.
October 1, 2025
·
6 min read
·
Annalee Armstrong
Press Releases
Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).
December 12, 2025
·
3 min read
Press Releases
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
October 13, 2025
·
12 min read
Press Releases
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
December 15, 2025
·
7 min read
1 of 7,412
Next
